August 7, 2019 / 11:39 PM / 2 months ago

Roche loses another bid to halt Amgen sales of biosimilar cancer drug

A federal appeals court on Wednesday denied a request by Roche Holdings subsidiary Genentech Inc for a temporary order keeping a biosimilar version of its cancer drug Herceptin marketed by Amgen Inc off the U.S. market.

The U.S. Court of Appeals for the Federal Circuit said in a one-page order that Genentech had not established that it was entitled to an injunction during the pendency of its appeal of a lower court ruling that allowed Amgen to launch its copycat version.

To read the full story on Westlaw Practitioner Insights, click here:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below